CI

At a glance

ClinicalIndex Comparison Record
Phase 1Recruiting· 10 target
Drug / intervention
CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cellsbiological
Likely dose
Not stated in record
Key inclusion· 5
  • ✓Age older than 6 months
  • ✓Confirmed expression of CLL-1, CD123 and/or CD33 in blast AML by immuno-histochemical staining or flow cytometry
  • ✓Adequate bone marrow, liver and renal function per specified lab requirements
  • ✓Ability to understand and provide written informed consent
Key exclusion· 7
  • ✕Severe illness or medical condition that would not permit management per protocol, including active uncontrolled infection
  • ✕Active bacterial, fungal or viral infection not controlled by adequate treatment
  • ✕Known HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
  • ✕Pregnant or nursing women

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04010877
NCT04010877Phase 1RecruitingOn Track
CompareCT.gov

Multi-center Phase I/II Clinical Trial of Multiple CAR T Cells for Treating Acute Myeloid Leukemia

Shenzhen Geno-Immune Medical Institute·interventional·Posted Jul 8, 2019·Updated Jun 23, 2026

In Brief

A Phase 1 clinical trial evaluating CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells for Acute Myeloid Leukemia. Currently recruiting, targeting 10 participants across 1 site.

Detailed Summary

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multiple CAR T-cell therapy which combines CAR T cells against CLL-1 with CAR T cells targeting CD123 or CD33 in patients with relapsed and refractory AML. The study also aims to learn more about the function of CAR T cells and their persistency in AML patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia
CountriesChina
Collaborators--

Timeline

Phase 1Recruiting
20202021202220232024202520262027202820292030
First PostedJul 8, 2019
Enrollment StartAug 1, 2025
Primary CompletionJul 31, 2028
Study CompletionDec 31, 2029
TodayJul 1, 2026
Enrollment to primary: 3 yearsPosted 7.0 years agoPrimary completion in 2.1 years

Arms & Interventions

Multiple CAR T cells to treat AMLexperimental

Multiple CAR T cells to treat AML

Biological: CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells

Interventions

CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cellsbiological

Infusion of CLL-1, CD33 and/or CD123-specific CAR-T cells